Meeting
2019 ASCO Annual Meeting
Tumor mutational burden (TMB) and PD-L1 expression as predictors of response to immunotherapy (IO) in NSCLC.
Authors
Emily Castellanos
Flatiron Health, New York, NY
Emily Castellanos , Jeremy Snider , Siraj Mahamed Ali , Daniel Backenroth , Lee A. Albacker , Karthikeyan Murugesan , Gerald Li , Garrett M. Frampton , Brian Michael Alexander , Kenneth Robert Carson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2630)
DOI
10.1200/JCO.2019.37.15_suppl.2630
Abstract #
2630
Poster Bd #
274
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
RET-rearranged lung cancers: Immunophenotype and response to immunotherapy.
First Author: Joshua K. Sabari
Poster
2023 ASCO Annual Meeting
A phase II trial of JDQ443 in KRAS G12C-mutated NSCLC with PD-L1 expression <1% or PD-L1 expression ≥1% and an STK11 co-mutation.
First Author: Colin R Lindsay
Poster
2022 ASCO Annual Meeting
Outcomes of single-agent PD-(L)-1 versus combination with chemotherapy in patients with PD-L1-high (≥ 50%) lung cancer.
First Author: Arielle Elkrief
Poster
2021 ASCO Annual Meeting
Association of a very high tumor mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer.
First Author: Biagio Ricciuti